Autophagy in major human diseases
- PMID: 34459017
- PMCID: PMC8488577
- DOI: 10.15252/embj.2021108863
Autophagy in major human diseases
Abstract
Autophagy is a core molecular pathway for the preservation of cellular and organismal homeostasis. Pharmacological and genetic interventions impairing autophagy responses promote or aggravate disease in a plethora of experimental models. Consistently, mutations in autophagy-related processes cause severe human pathologies. Here, we review and discuss preclinical data linking autophagy dysfunction to the pathogenesis of major human disorders including cancer as well as cardiovascular, neurodegenerative, metabolic, pulmonary, renal, infectious, musculoskeletal, and ocular disorders.
Keywords: aging; cancer; inflammation; metabolic syndromes; neurodegeneration.
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Conflict of interest statement
A.B. is cofounder of CASMA Therapeutics Inc., Advisory Board member of Next Generation Diagnostics and of Avilar Therapeutics. K.C. has received research support from Pfizer, Takeda, Pacific Biosciences, and AbbVie; consulted for or received an honorarium from PureTech Health, Genentech, and AbbVie; and holds U.S. patent 10,722,600 and provisional patents 62/935,035 and 63/157,225. A.M.K.C. is a cofounder, stock holder and serves on the Scientific Advisory Board for Proterris, which develops therapeutic uses for carbon monoxide. A.M.K.C. also has a use patent on CO. G.K is a cofounder and advisor of EverImmune, Samsara Therapeutics, and Therafast Bio as well as advisor for The Longevity Labs (TLL). F.M. is a founder, is advisor, and has equity interests in The Longevity Labs (TLL) and Samara Therapeutics. D.C.R is a consultant for Aladdin Healthcare Technologies SE, Drishti Discoveries, and Nido Biosciences. L.G. has received research funding from Lytix Biopharma and Phosplatin, as well as consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. RKA is cofounder of Pinpoint Therapeutics and advisor for Deciphera, Sprint Biosciences, Merck, and Immunacell. He gets research funding for clinical trials from Novartis, Bristol Myers Squibb, Pfizer, and Deciphera. J.Y. is a consultant for Denali Therapeutics, Sanofi, and Nido. All other authors have no conflicts of interest to disclose.
Figures


References
Publication types
MeSH terms
Substances
Grants and funding
- BBS/E/B/000C0413/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- 22903/CRUK_/Cancer Research UK/United Kingdom
- R01 AG021904/AG/NIA NIH HHS/United States
- 15816/CRUK_/Cancer Research UK/United Kingdom
- P01 CA114046/CA/NCI NIH HHS/United States
- R01 CA260249/CA/NCI NIH HHS/United States
- R35 GM131689/GM/NIGMS NIH HHS/United States
- R01 AG064892/AG/NIA NIH HHS/United States
- R01 CA216242/CA/NCI NIH HHS/United States
- R01 AG038664/AG/NIA NIH HHS/United States
- R01 CA200310/CA/NCI NIH HHS/United States
- R01 CA251726/CA/NCI NIH HHS/United States
- R15 GM102846/GM/NIGMS NIH HHS/United States
- BBS/E/B/000C0417/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- UKDRI-2002/MRC_/Medical Research Council/United Kingdom
- 28686/CRUK_/Cancer Research UK/United Kingdom
- P01 AG031782/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources